Navigation Links
Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
Date:1/16/2008

LA JOLLA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) did not authorize or endorse the release of an Equity Research Profile on the company issued by Proteus Equity Research Partners, a privately-held equity research company, nor the associated press release announced earlier today.

Further, The Blaine Group is the only authorized public and investor relations firm retained by Immunosyn Corporation at this time.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com)

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
2. MB Software Corporation Reaches Agreement with Keystone Equity Partners
3. Private Equity Firms Acquire American Laser Centers
4. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
5. Health Fitness Announces Non-Cash Adjustment and Restatement of 2006 Equity Investment Transaction Resulting in Delay for Filing Third Quarter Form 10-Q
6. Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank
7. StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) Review Issued By Scimitar Equity Research, Inc.
8. SEIU Applauds Bipartisan Leadership of Sen. Finance Committee in Push for Greater Oversight of Private Equity Takeovers of Nursing Homes
9. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
10. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
11. With the Largest-Ever Buyout of a National Nursing Home Chain Pending ... New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
(Date:2/23/2017)... ... 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti ... Indiegogo campaign . Individuals are now able to contribute to the local initiative, ... as a participating patient or through an Indiegogo donation. The entirety of proceeds will ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Carlos Gutierrez ... He has also continued to spiritually evolve, which is the purpose of everyone in ... Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers to expand ...
(Date:2/22/2017)... Tampa, Fla. (PRWEB) , ... February 22, 2017 ... ... the field of regenerative medicine in recent years. The technology is so cutting ... sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the ... once again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping ... episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology: